Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0006142 (breast cancer)
 160,383 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Frequencies of 25 HLA antigens in 526 Caucasian patients were compared to those in 629 healthy controls who were HLA-typed between September 1975 and February 1977. Haplotypes were compared for 711 patients and 549 controls typed between September 1974 and December 1976. Frequency deviations were found in those with ALL, AML, breast cancer, lymphoma and ovarian cancer, but only the increase in A29 in AML patients was statistically significant when corrected for the number of specificities. Interesting associations, when compared with earlier studies, include elevation of AW24 in both ALL and AML patients and increased B27 in ALL patients. Significant haplotype differences were increased A3-B8 and absence of A1-BW17 in ALL patients and increased A11-B5 and A2-BW40 as well as absence of A2-B5 in AML patients.
 ...
PMID:HLA frequencies in cancer: a third study. 28 33

HLA determinations were made at the time of diagnosis among a lot of 141 patients with breast cancer. Values of relative risk as well as frequencies of antigens at the first and the second locus were confronted to data found in a control population. Subdivisions of the neoplastic population according to hormonal status and parity led to the emergence of significant differences: frequency of A28 in menopausal nulliparous women with breast cancer is 26 vs. 7% in controls (p corrected = 0.038) with relative risk = 6.63 (p 0.001).
 ...
PMID:Positive correlation between breast cancer incidence and HLA antigens. 47 27

HLA antigens and haplotypes were studied in 50 women with infiltrating ductal carcinoma of the breast, from the Basque provinces and Navarra, and in a comtrol group consisted of 166 healthy persons from the same geographical area. A greater incidence of HLA-B7 and B26 was observed in the breast cancer group if compared with the frequency of occurrence of these antigens in the Spanish population. However, when compared with Navarra-Basque population, no significant differences were observed. The study of the haplotype frequencies in breast cancer showed a greater incidence of the A9, B27 and A10, B14 haplotypes than in the normal population. However, the significance of D values disappeared after making the necessary correction for the number of antigens tested. The major histocompatibility system has a variety of functions which have not yet been documented but that might predispose to disease. It is certainly probable that there will be multiple mechanisms underlying HLA and cancer associations, however so far none of the data available suggest the presence of an immune response gene linked with breast cancer.
 ...
PMID:Breast cancer and histocompatibility antigens. 53 25

Two-hundred-and-forty-nine Indian cancer patients were tested for 39 HLA antigens and the antigen frequencies were compared with those of 603 control subjects. Comparisons were also made between cancer patients and controls for each ethnic group and for each site of cancer. There was an increase in the frequency of the HLA antigens A11 and Bw52 in patients with malignancies. Heterozygosity at the B locus was significantly increased in patients with cancer of the breast. The Aw24, B17 haplotype was also associated with breast cancer.
 ...
PMID:HLA and cancer in South African Indians. 54 44

HLA (A and B) antigen frequencies in 100 women with breast cancer were compared with those in 2 groups of cancer-free control women: the first control group (263 subjects) were age-unmatched, and the second (75 subjects) age-matched. The mean age and standard deviation were 56 +/- 13 years for the patient group, 25 +/- 3 years for the first control group, and 53 +/- 10 years for the second. It was first noted that HLA-B13 was significantly less prevalent among the patients with breast cancer when compared to the first control group (1% versus 7.2%, p = 0.025). However, when the patient group was compared to the second control group, no difference was found in the frequency of HLA-B13 (1% versus 1.3%, p = 0.80) or any other antigens. Age can be an important variable in a study of correlation between HLA and disease.
 ...
PMID:Lack of association between breast cancer and HLA (A and B) specificities: importance of age-matched controls. 90 21

Sera from breast cancer patients and from female controls were tested for inhibition of lysis of antibody-coated target cells by human leukocytes (K cells). Sera from 39% of breast cancer patients, but from only 8% of controls, inhibited lysis by more than 30%. This inhibition was unrelated to the stage of the disease, the patient's age or whether the patient was pre- or post-operative. Inhibition was apparently not due to anti-HLA antibodies and did not correlate with the IgG level or anti-complementary activity of the serum. On fractionation by gel-filtration, inhibitory activity was found in fractions of higher molecular weight than IgG. As no IgG could be detected in these fractions, inhibition is probably not due to immune complexes containing IgG antibody. The inhibitory factor may well contribute to the immunosuppressed status of a proportion of breast cancer patients.
 ...
PMID:Inhibition of K cell function by human breast cancer sera. 100 90

Cytokine-induced modulation of HLA expression on the cell surface of four human breast cancer cell lines was determined by continuous flow immunocytofluorometry with the aid of monoclonal antibodies directed to a non-polymorphic determinant of HLA class I and class II (DR) antigen. IFN-gamma and IFN-alpha were potent inducers of HLA class I in all examined cell lines, with decreasing inducibility as follows: BT-20, ZR-75-1, MCF-7 and MDA-MB-468 cells. HLA class II (DR) antigen was highly inducible by IFN-gamma in ZR-75-1 cells, followed by BT-20, MDA-MB-468 and MCF-7 cells. IFN-alpha increased the cell surface expression of DR antigen only in ZR-75-1 cells. IL-1-alpha induced a moderate level of HLA class I antigen in ZR-75-1, BT-20 and MDA-MB-468 cells, and HLA class II (DR) expression only in ZR-75-1 cells. This pattern of cell line inducibility by IL-1-alpha was similar to that induced by TNF-alpha. Differences in inducibility of HLA antigens on human breast cancer cell lines induced by different cytokines may reflect the differences in cytokine inducibility of the original tumor cells.
 ...
PMID:Cytokine (IFN-alpha, IFN-gamma, IL-1-alpha, TNF-alpha)-induced modulation of HLA cell surface expression in human breast cancer cell lines. 143 41

Over the last 20 years allogeneic bone marrow transplantation from an HLA-identical sibling donor has become the treatment of choice for a number of human haematological malignancies, severe aplastic anaemia, some congenital diseases of the immune and haemopoietic systems, and some inborn errors of metabolism. Recently, the successful introduction of HLA-matched unrelated donor transplants, convenient T cell depletion technology, combination immunosuppressive therapy to minimise graft-versus-host disease, blood products that are seronegative for cytomegalovirus, effective antiviral agents, and cloned haemopoietic and immune system growth factors have markedly increased the scope of bone marrow transplantation. Additionally, autologous transplantation appears to have promise especially in lymphoma and breast cancer.
 ...
PMID:Bone marrow transplantation. 144 94

There are four classical forms of immunotherapy: active, adoptive, restorative, and passive, and perhaps a fifth form, cytomodulatory, the upregulation of tumor-associated and HLA antigens to make tumors more recognizable by the immune system. Our 5-year experience with low-dose cyclophosphamide (CY) (350 mg/m2) before low-dose interleukin-2 (IL-2) (21.6 million IU/m2/d x 5 d/wk x 2 wk per course by IV bolus) is reviewed as an example of combination chemotherapy and immunotherapy. Twenty-six percent (10 of 39 evaluable patients) of patients with melanoma had major clinical responses; one other patient (2%) has had more than 48 months of response after a 40% regression of all tumors. Median survival was 18 months for responders and 8 months for the group as a whole. Eleven of 41 patients (27%) lived at least 12 months and four (10%) lived at least 2 years. Liver metastases regressed in 4 of 10 cases, with responses in lung, adrenal, skin, and lymph nodes but no bone. Toxicity was tolerable. A correlation between cytolysis of lymphocytes against a natural killer-resistant melanoma cell line (LAK-like activity) was found, but the role of LAK cells in vivo remains uncertain. No effect was noted in 15 patients with renal cancer, but regressions of breast cancer were found in a shortened trial with 13 patients. While the necessity for CY has not been established in these studies, the regimen of CY + IL-2 as it stands appears to have some clinical efficacy in at least two cancers.
 ...
PMID:Chemotherapy in combination with biomodulation: a 5-year experience with cyclophosphamide and interleukin-2. 155 79

The phenotype and activation status of lymphocytes from the peripheral blood and axillary lymph nodes of 40 patients with breast cancer were analysed using flow cytometry and compared with lymphocytes from the blood and lymph nodes of 7 control subjects. There was little difference in the overall proportions of T and B lymphocytes but there was a much larger population of B cells bearing surface IgG and a greater number of CD4+ helper T cells, particularly in the regional nodes, in the breast cancer patients. Many more T cells in the cancer patients were found to be carrying the HLA DR and Tac antigens. The axillary lymph nodes were the major site of B cells and CD4+ T cells whilst the primary tumour was the source of the CD8+ suppressor/cytotoxic T cells. Any immune response appeared to be largely loco-regional and may therefore destroyed by conventional surgery or radiotherapy.
 ...
PMID:Flow cytometric analysis of tumour-draining lymph nodes in breast cancer patients. 159 Oct 50


1 2 3 4 5 6 7 8 9 10 Next >>